相似文献
1
Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option?
Thorax. 1998 Feb;53(2):114-6. doi: 10.1136/thx.53.2.114.
2
Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Antiviral Res. 1996 Mar;29(2-3):269-77. doi: 10.1016/0166-3542(95)00907-8.
3
Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
J Dent Res. 1999 Dec;78(12):1773-6. doi: 10.1177/00220345990780120201.
4
Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture.
J Infect Dis. 2002 Jun 1;185(11):1606-13. doi: 10.1086/340512. Epub 2002 May 17.
5
Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi.
J Infect Dis. 1997 Sep;176(3):740-7. doi: 10.1086/514098.
6
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
J Clin Invest. 1995 Jul;96(1):456-64. doi: 10.1172/JCI118056.
7
Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
Oral Dis. 2002 May;8(3):160-7. doi: 10.1034/j.1601-0825.2002.01807.x.
8
Glycosaminoglycans regulate elastase inhibition by oxidized secretory leukoprotease inhibitor.
Am J Physiol. 1997 Mar;272(3 Pt 1):L533-41. doi: 10.1152/ajplung.1997.272.3.L533.
9
Efficient production of the C-terminal domain of secretory leukoprotease inhibitor as a thrombin-cleavable fusion protein in Escherichia coli.
Protein Eng. 1996 Jan;9(1):101-6. doi: 10.1093/protein/9.1.101.
10
Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
Oral Dis. 1997 May;3 Suppl 1:S64-9. doi: 10.1111/j.1601-0825.1997.tb00377.x.
引用本文的文献
1
Synthesis of secretory leukocyte protease inhibitor using cell-free protein synthesis system.
Odontology. 2024 Oct;112(4):1103-1112. doi: 10.1007/s10266-024-00910-8. Epub 2024 Mar 19.
2
The secretory leukocyte protease inhibitor (SLPI) in pathophysiology of non-communicable diseases: Evidence from experimental studies to clinical applications.
Heliyon. 2024 Jan 17;10(2):e24550. doi: 10.1016/j.heliyon.2024.e24550. eCollection 2024 Jan 30.
3
A Comprehensive Multi-Omic Approach Reveals a Relatively Simple Venom in a Diet Generalist, the Northern Short-Tailed Shrew, Blarina brevicauda.
Genome Biol Evol. 2020 Jul 1;12(7):1148-1166. doi: 10.1093/gbe/evaa115.
4
Non-Reflex Defense Mechanisms of Upper Airway Mucosa: Possible Clinical Application.
Physiol Res. 2020 Mar 27;69(Suppl 1):S55-S67. doi: 10.33549/physiolres.934404.
5
Persistent Breeding-Induced Endometritis in Mares - a Multifaceted Challenge: From Clinical Aspects to Immunopathogenesis and Pathobiology.
Int J Mol Sci. 2020 Feb 20;21(4):1432. doi: 10.3390/ijms21041432.
6
Coralsnake Venomics: Analyses of Venom Gland Transcriptomes and Proteomes of Six Brazilian Taxa.
Toxins (Basel). 2017 Jun 8;9(6):187. doi: 10.3390/toxins9060187.
7
Oestrous cycle-dependent equine uterine immune response to induced infectious endometritis.
Vet Res. 2016 Nov 8;47(1):110. doi: 10.1186/s13567-016-0398-x.
8
Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate Antibiotics.
PLoS One. 2016 Jan 5;11(1):e0146192. doi: 10.1371/journal.pone.0146192. eCollection 2016.
9
Deep sequencing of the uterine immune response to bacteria during the equine oestrous cycle.
BMC Genomics. 2015 Nov 14;16:934. doi: 10.1186/s12864-015-2139-3.
10
Quantitative high-throughput profiling of snake venom gland transcriptomes and proteomes (Ovophis okinavensis and Protobothrops flavoviridis).
BMC Genomics. 2013 Nov 14;14:790. doi: 10.1186/1471-2164-14-790.
本文引用的文献
1
Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi.
J Infect Dis. 1997 Sep;176(3):740-7. doi: 10.1086/514098.
2
Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines.
J Infect Dis. 1997 Jul;176(1):300-3. doi: 10.1086/517272.
3
Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?
Cell. 1997 Jan 10;88(1):1-4. doi: 10.1016/s0092-8674(00)81850-4.
4
Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.
Thorax. 1996 Dec;51(12):1273-4. doi: 10.1136/thx.51.12.1273.
5
Antibacterial activity of antileukoprotease.
Infect Immun. 1996 Nov;64(11):4520-4. doi: 10.1128/iai.64.11.4520-4524.1996.
6
Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Antiviral Res. 1996 Mar;29(2-3):269-77. doi: 10.1016/0166-3542(95)00907-8.
7
Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis.
Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):1056-60. doi: 10.1164/ajrccm/148.4_Pt_1.1056.
8
Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor.
Am Rev Respir Dis. 1993 Feb;147(2):442-7. doi: 10.1164/ajrccm/147.2.442.
9
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
J Clin Invest. 1995 Jul;96(1):456-64. doi: 10.1172/JCI118056.
10
Antileukoprotease in sputum during bronchial infections.
Chest. 1986 May;89(5):731-6. doi: 10.1378/chest.89.5.731.
Zotero 插件